Key questions in antiretroviral therapy: Italian Consensus Workshop (2005)

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1055-1064

  Carosi, G ^a   Torti, Carlo ^a   Andreoni, M ^b   Angarano, G ^c   Antinori, A ^d   Bonora, S ^e   Borderi, M ^f   Castagna, A ^g   Castelli, F ^a   Cauda, R ^h   Chiodo, F ^f   D'Arminio Monforte, A ⁱ   De Luca, A ^h   Di Perri, G ^e   Dianzani, F ^j   Filice, G ^k   Galli, M ^l   Lazzarin, A ^g   Maggiolo, F ^m   Maserati, R ^k   Mazzotta, F ⁿ   Moroni, M ^l   Perno, C F ^b   Vullo, V ^d   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ SAN PAOLO HOSPITAL   (Italy)

^j UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^k UNIVERSITY OF PAVIA   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m OSPEDALI RIUNITI   (Italy)

ⁿ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

more..

Author keywords

Guidelines; HAART; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ITALY; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MEDICAL SOCIETY; MEDICAL SPECIALIST; PANCREATITIS; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; TREATMENT FAILURE; TREATMENT PLANNING; UNITED STATES; VIROLOGY; WORKSHOP; CONFERENCE PAPER;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS;

EID: 33749175088     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl113     Document Type: Review

References (35)

1. 6/I. AIDS 2002; 16:1371-81.
2. 3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003; 36: 812-15.
3. Wang C, Vlahov D, Galai N et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: Implications for when to initiate therapy. J Infect Dis 2004; 190: 1046-54.
4. Holmberg SD, Palella FJ, Lichtenstein KA et al. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39: 1699-704.
5. Smith CJ, Sabin CA, Lampe FC et al. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antiviral Ther 2005; 10: 459-67.
6. Maggiolo F, Ripamonti D, Gregis G et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled prospective trial. AIDS 2004; 18: 439-46.
7. 3 reach same mortality rates as general population: APROCO and aquitane cohorts, France. In: Program and Abstracts of the Tenth European AIDS Conference/ EACS, Dublin, Ireland, 2005. Abstract PE 18.4/8, p. 138. European AIDS Clinical Society, Paris, France.
8. Carosi G, Puoti M, Antonucci G et al. Antiretroviral therapy in chronic liver disease: Focus on HIV/HCV coinfection - statements of the First Italian Consensus Workshop, AIDS Rev 2005; 7: 161-7.
9. 3. J Infect Dis 2005; 192: 950-7.
10. Kapadia F, Vlahov D, Donahoe RM et al. The role of substance abuse in HIV disease progression: Reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41: 1027-34.
11. Fischl M, Bassett R, Collier A et al. Randomized, controlled trial of lopinavir/ritonavir + efavirenz vs efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 162, p. 123. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/2005/cd/ Abstracts/24223.htm (1 March 2006, date last accessed).
12. Tebas P, Zhang J, Yarasheski K et al. Switch to a protease inhibitor containing/nucleoside reverse transcriptase inhibitor-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density. The results of a prospective randomized trial, ACTG 5125s. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 40, p. 79. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/2005/cd/Abstracts/ 24545.htm (1 March 2006, date last accessed).
13. Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost effectiveness analysis. Clin Infect Dis 2005; 41: 1316-23.
14. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection N Engl J Med 2002; 346: 2039-46.
15. Malan N, Krantz E, David N et al. Efficacy and safety of atazanavir based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48 week results from A1424-089. In: Program and Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract LB107, p. 87. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/2006/Abstracts/27965.HTM (1 March 2006, date last accessed).
16. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naïve, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005; 191: 2046-52.
17. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
18. Gallant JE, Staszewski S, Pozniak A et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial. JAMA 2004; 292: 191-201.
19. Podzamczer D, Ferrer E, Sanchez P et al. Toxicity and efficacy of 3TC/ EFV associated with stavudine or abacavir in antiretroviral-naïve patients: 48-week results of a randomized open and multicenter trial (ABCDE Study). In: Program and Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 716, p. 330. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/2004/cd/Abstract/ 716.htm (1 March 2006, date last accessed).
20. Sanchez-Conde M, de Mendoza C, Jiemenez-Nacher I et al. Reductions in stavudine dose might ameliorate mitochondrial associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6: 197-202.
21. De Jesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. Clin Infect Dis 2004; 39: 1038-46.
22. Gallant JE, De Jesus E, Arribas JR et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
23. Barrios A, Rendon A, Negredo E et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19: 569-75.
24. Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62.
25. Pai N, Tulsky J, Lawrence J et al. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; (4): CD005482.
26. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART study. In: Program and Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. AbstractLB106, p. 87. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://retroconference.org/2006/Abstracts/28085.HTM (1 March 2006, date last accessed).
27. 3. J Infect Dis 2005; 192: 1787-93.
28. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 1537-44.
29. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.
30. d'Arminio-Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the Italian Cohort of Antiretroviral Naïve Patients. J Acquir Immune Defic Syndr 2005; 38: 407-16.
31. Antinori A, Cingolani A, Perno CF. Structured treatment interruption in HIV-infected patients failing on multidrug therapy: Is there a future for this strategy? AIDS 2005; 19: 1691-4.
32. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 6, 2005. http://AIDSinfo.nih.gov (1 March 2006, date last accessed).
33. Gazzard B on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005; 6 Suppl 2: 1-61.
34. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65.
35. Delfrassy JF on behalf of the 'Direction Generale de la Santè' expert panel. Prise en charge des personnes infectèes par le VIH. Ed. Flammarion 2004 - ISBN: 2-257-10198-7.